Enduring Material

• Understand the role of the Children’s Oncology Group in pediatric cancer research.
• Describe the potential for molecular profiling to guide pediatric cancer treatment and barriers to implementation.
• Describe barriers to new agent development in pediatric oncology.

• Connecticut Children's Office of Continuing Medical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The Connecticut Children's designates this enduring material for a maximum of 1 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology^™ (MOCA^®) program, known as MOCA 2.0^®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn their required annual part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery's Continuing Certification program(formerly known as MOC). It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Douglas Hawkins, MD, Professor, Hematology-Oncology at Seattle Children's Hospital and Professor of Pediatrics at the University of Washington School of Medicine, Chair, Children's Oncology Group has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Bayer HealthCare Pharmaceuticals - Contracted Research - Relationship Has Not Ended
• Pfizer - Contracted Research - Relationship Has Not Ended
• Eli Lilly - Contracted Research - Relationship Has Not Ended
• Jazz Pharmaceuticals - Contracted Research - Relationship Has Not Ended
• Merck Sharp & Dohme - Contracted Research - Relationship Has Not Ended
• Genentech - Contracted Research - Relationship Has Not Ended
• AstraZeneca UK Limited - Contracted Research - Relationship Has Not Ended

Any financial relationship that was found to be relevant has been mitigated.

Connecticut Children’s is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Connecticut Children's designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only credits commensurate with the extent of their participation in the various activities. MOC Part 2: Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 1 MOC points in the American Board of Pediatrics’ (ABP), American Board of Otolaryngology-Head and Neck Surgery’s (ABOHNS), American Board of Anesthesiology (ABA), and the and the American Board of Surgery’s (ABS) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit. • Conflict of interest: All faculty participating in Continuing Medical Education activities sponsored by Connecticut Children’s are required to disclose to the program audience any actual or perceived conflict of interest related to the content of their presentation. Program planners have an obligation to resolve any actual conflicts of interest and share with the audience any safeguards put in place to prevent commercial bias from influencing the content. Douglas Hawkins, MD, has disclosed a financial relationship with Bayer HealthCare Pharmaceuticals, Pfizer, Eli Lilly, Jazz Pharmaceuticals, Merck Sharp & Dohme, Genentech, and AstraZeneca UK Limited as a contracted researcher. All relevant financial relationships have been mitigated according to the ACCME guidelines. The speaker(s) will not be discussing the use of any off-label product.

This activity is not commercially supported.

• Connecticut Children's is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Connecticut Children's takes responsibility for the content, quality, and scientific integrity of this CME activity.

75 %

100 %

9/2/2025